GHRP-2 Peptide Shows Anti-Inflammatory Effects in Human Ovarian Cells
Background
Inflammation within the ovaries can significantly impair the function of granulosa cells, which are crucial for follicle development and hormone production. This dysfunction can contribute to various reproductive disorders, including infertility and conditions like Polycystic Ovary Syndrome (PCOS). Understanding novel mechanisms to attenuate ovarian inflammation is essential for developing new therapeutic strategies to improve reproductive health.
Results
GHRP-2 demonstrated a significant dose-dependent attenuation of the inflammatory response in the treated cells. The most pronounced effect was observed at 1 µM GHRP-2, which led to a 65% reduction (p<0.001) in IL-6 (an inflammatory cytokine) secretion and a 58% decrease (p<0.001) in TNF-α (another key inflammatory mediator) compared to PKC-activated control cells. Furthermore, GHRP-2 treatment at the highest dose suppressed the expression of pro-inflammatory enzymes, reducing COX-2 by 2.3-fold and iNOS by 1.8-fold. The peptide also significantly inhibited the activation of NF-κB (a central transcription factor regulating inflammatory gene expression) by 45% (p<0.01), indicating a broad anti-inflammatory mechanism.
Why It Matters
This research highlights GHRP-2 as a potential novel therapeutic agent for mitigating ovarian inflammation, which could have significant implications for treating conditions like PCOS or improving fertility outcomes. Its ability to suppress key inflammatory cytokines and pathways suggests a robust anti-inflammatory profile. These findings warrant further investigation into GHRP-2's efficacy and safety in in vivo models, paving the way for potential human clinical trials to explore its application in reproductive medicine.